Answers are grounded in this paper and cite their sources.
The special issues of the Journal of International Medical Research provide readers with an opportunity to learn more about various important issues in health care, research, or policy from several perspectives. This special issue present articles on the theme of risk–benefit analysis of medicines. Medicines provide therapeutic benefits (the successful treatment of the condition for which the drug is indicated) and other types of benefits such as improved quality of life. Unfortunately, medicines also carry risks of adverse drug reactions, which can vary from minor symptoms (such as nausea, vomiting, or headache) to rare, severe reactions (such as anaphylactic reaction, liver failure, or cancer). A new chemical entity, upon emerging from the drug discovery process, is tested extensively in animals (preclinical research) and humans (clinical trials) to establish its risk–benefit profile. In preclinical research, the efficacy data for a new chemical entity are obtained from specific animal models of the target disease among various species and strain of animals, whereas safety data are obtained from various toxicological studies. The sponsor submits all information from preclinical studies to regulatory authorities in the form of an investigational new drug application. The risk–benefit ratio from preclinical studies determines whether a candidate drug is suitable for first-inhuman testing. If found suitable, the drug undergoes testing in various phases of clinical trials for risk–benefit analysis, a continuous process. After successful completion of all phases of clinical trials, regulators assess the information available at that specific moment, in the form of a new drug application, with regard to the risks and benefits, and authorized the product if the benefits outweigh the risks. This balance is valid at a given point of time, but may change later once the drug is on the market as a result of exposure in a large number of patients, concomitant medications and diseases, longterm exposure, confounding factors, and uncontrolled conditions. For example, benefit might be 90% and risk 15% when the first periodic safety update report (PSUR) is submitted. These percentages might have changed when the fourth PSUR is submitted (benefit 80% and risk 50%). Thus, multiple drugs that were initially found to be very successful in a number of patients were unfortunately later found to cause
No takes yet. Share an insight, caveat, or question.
Anoop Kumar (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: